Health Economics›Non-small cell lung cancer nonsquamous›Advanced or metastatic disease first-line

Advanced or metastatic disease first-line

Non-small cell lung cancer nonsquamous · 32 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 23 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin, Pemetrexed, Pembrolizumab Variant #01	—	R 96 550	21d	8.8 mo	21.3 mo	36	R 3 351 004 PFS proxy	7
Cisplatin, Pemetrexed, Pembrolizumab Variant #01	—	R 95 653	21d	8.8 mo	22.0 mo	35	R 2 924 218 PFS proxy	6
Carboplatin, Pemetrexed, Ipilimumab, Nivolumab Variant #01 Partial	—	R 93 178	21d	—	15.8 mo	3	R 186 356 PFS proxy	1
Cisplatin, Pemetrexed, Ipilimumab, Nivolumab Variant #01 Partial	—	R 92 282	21d	—	15.8 mo	3	R 184 563 PFS proxy	1
Carboplatin and nab-Paclitaxel (CnP) and Atezolizumab Variant #01	—	R 80 722	21d	—	18.6 mo	5	R 354 143 PFS proxy	1
Ipilimumab and Nivolumab Variant #01 Partial	—	R 78 615	42d	~11.5 mo	~29.2 mo	~9	~R 707 538 PFS proxy · indirect	13
ABCP Variant #05	—	R 63 886	21d	8.9 mo	19.0 mo	5	R 316 784 PFS proxy	3
Carboplatin and Paclitaxel (CP) and Bevacizumab Variant #01	—	R 48 987	28d	8.2 mo	14.7 mo	12	R 473 840 PFS proxy	8
Carboplatin, Pemetrexed, Atezolizumab Variant #01	—	R 45 817	21d	7.9 mo	17.5 mo	5	R 227 749 PFS proxy	2
Cisplatin, Pemetrexed, Atezolizumab Variant #01	—	R 44 921	21d	8.0 mo	17.5 mo	5	R 224 163 PFS proxy	1
Carboplatin, Pemetrexed, Bevacizumab Variant #01	—	R 44 549	21d	6.8 mo	12.6 mo	7	R 297 280 PFS proxy	2
Cisplatin, Pemetrexed, Bevacizumab Variant #03	—	R 43 652	21d	5.6 mo	—	6	R 261 915 PFS proxy	2
Carboplatin and nab-Paclitaxel (CnP) Variant #01	—	R 41 178	21d	—	13.9 mo	4	R 164 713 PFS proxy	1
Cisplatin and Gemcitabine (GC) and Bevacizumab Variant #01	—	R 34 213	21d	—	—	7	R 235 264 PFS proxy	2
Carboplatin and Paclitaxel (CP), Bevacizumab, Nivolumab Variant #01 Partial	—	R 32 793	21d	11.4 mo	31.6 mo	7	R 226 743 PFS proxy	3
Atezolizumab monotherapy Variant #01	—	R 31 255	21d	20.2 mo	—	16	R 500 074 PFS proxy	1
Carboplatin, Pemetrexed, Cemiplimab Variant #01 Partial	—	R 14 563	21d	—	21.5 mo	36	R 481 451 PFS proxy	2
Carboplatin, Pemetrexed, Tislelizumab Variant #02 Partial	—	R 14 563	42d	9.8 mo	—	7	R 100 601 PFS proxy	1
Carboplatin and Pemetrexed Variant #01	—	R 14 563	21d	5.1 mo	14.9 mo	4	R 58 251 PFS proxy	18
Carboplatin, Pemetrexed, Sintilimab Variant #01 Partial	—	R 14 563	21d	8.9 mo	24.2 mo	35	R 468 226 PFS proxy	2
Carboplatin, Pemetrexed, Sugemalimab Variant #01 Partial	—	R 14 563	21d	9.0 mo	25.3 mo	5	R 71 476 PFS proxy	4
Carboplatin, Pemetrexed, Camrelizumab Variant #01 Partial	—	R 14 563	21d	11.3 mo	27.1 mo	7	R 100 601 PFS proxy	3
Cisplatin, Pemetrexed, Cemiplimab Variant #01 Partial	—	R 13 666	21d	—	21.5 mo	36	R 477 865 PFS proxy	2
Cisplatin, Pemetrexed, Sintilimab Variant #01 Partial	—	R 13 666	21d	8.9 mo	24.2 mo	35	R 464 640 PFS proxy	2
Cisplatin and Pemetrexed Variant #01	—	R 13 666	21d	5.0 mo	13.4 mo	7	R 94 340 PFS proxy	12
Cisplatin, Pemetrexed, Tislelizumab Variant #02 Partial	—	R 13 666	42d	9.8 mo	—	7	R 95 222 PFS proxy	1
Carboplatin and Docetaxel (DCb) Variant #06	—	R 5 501	21d	—	14.7 mo	6	R 33 004 PFS proxy	—
Carboplatin and Gemcitabine (GCb) Variant #01	—	R 4 414	21d	~5.3 mo	~10.0 mo	~2	~R 8 829 PFS proxy · indirect	18
Gefitinib monotherapy Variant #01	—	R 4 278	28d	8.4 mo	20.6 mo	2	R 8 556 PFS proxy	4
Cisplatin and Gemcitabine (GC) Variant #01	—	R 3 933	21d	—	17.7 mo	6	R 23 595 PFS proxy	2
Cisplatin and Docetaxel (DC) Variant #05	—	R 3 185	21d	4.4 mo	—	3	R 9 556 PFS proxy	—
Carboplatin and Paclitaxel (CP) Variant #02	—	R 1 025	21d	6.1 mo	14.2 mo	18	R 18 445 PFS proxy	7

32 of 32 regimens shown